Welcome to

adthera logo

Innovative cell coaching for outstanding outcomes, your digital enabled cell therapy CDMO


23 May '24: adthera uniquely brings together development, manufacturing, quality and digital experience

21 May '24: Read some highlights of adthera's lunch and learn on 'all things QC'

14 May '24: Meet our office manager, Claire Parmar-Fleming

14 May '24: Read some of adthera's top tips when considering electronic notebooks

8 May '24: Listen to team adthera discuss considerations around digital systems and automation platforms

7 May '24: Here are adthera's top considerations when thinking about automated manufacturing platforms

1 May '24: adthera's top takeaways from the AMC 25th Technical Meeting

25 Apr '24: Meet adthera board member, Carol Lynch

25 Apr '24: Thank you for joining us on our open day

23 Apr '24: Meet our head of Strategy & Finance, Matthew Symes

17 Apr '24: Listen to adthera board member, Hilary Malone, on how adthera's digital approach will lead the way in regulatory

11 Apr '24: Fireside chat - Listen to our team discuss adthera's decentralized vision

25 Mar '24: adthera team evaluates handsfree heads-up display

21 Mar '24: Read the views of our Chief Manufacturing and Development Officer, Stuart Curbishley, from the Bioprocess Europe Meeting in Barcelona

20 Mar '24: Meet adthera scientists Shaun Day and Ridhi Gada

See how the adthera team supports the delivery of more cell therapies to patients, connect with us to find out more

Listen to adthera's Stuart Curbishley talk about our development capabilities and accelerated tech transfer via our mock cleanroom facility

Hear from our CEO Colin Sims on why you should choose adthera as your cell therapy partner

Connect with our team of experts to find out how we can accelerate the delivery of your cell therapies

adthera celebrates Neil McGowan on becoming an eligible Qualified Person after passing his viva

CEO Colin Sims with three observations, three themes and one conclusion from Pharmageddon Barcelona 2023 - read here on LinkedIn

adthera's Stuart Curbishley presenting at ARM Meeting on the Mesa: "How adthera bio can accelerate your therapy through clinical trial to market"

"The adthera team appears to have a different attitude to most - marrying digital-first and decentralized approaches." - Paul Simms, Impatient Health

adthera's Stuart Curbishley speaks at the International Society for Cell and Gene Therapy conference in Paris

"Cell and gene therapy CDMO adthera bio has announced its break from stealth" - Phacilitate

About Us

Our purpose is to ensure every patient has access to ATMPs.

adthera is your partner for innovative, optimised-quality, high-technology, cell & gene therapy-focussed development and manufacturing. We have an obsession on customer needs driving our vision of access to ATMP for patients.

We take your cell therapy ideas and make them into workable medical interventions for patients, all in a regulatory compliant and quality managed system, to get it right first time. Based on brilliant ideas and curious capable minds, we partner with biotechs and academic centres to bring novel ATMP therapies to market and thus to patients who urgently need them. We have highly personalised approaches from the patient to the client to the treatment outcome.

By being constantly curious and pushing the regulations and innovations in this novel area of medicine, we aim to make a positive difference on patient’s lives.

We live by our values of Integrity, Trust & Respect, Bravery, Agility, and Passion & Commitment.

About Us Image

What We Do

Process Development

  • Dedicated process development laboratory and team
  • Ability to handle pre-GMP materials, complete development runs with RUO materials
  • Mock-GMP suite for process simulations in a GMP environment in a cost-efficient manner

Manufacturing, Science & Technology

  • Partnering opportunities for tools and tech developers to beta test pre-market devices
  • Deep understanding of all major platforms for cell therapy manufacturing
  • Broad base of analytical skills to support in-process and release assay development and validation

Clinical Manufacturing

  • Access to 4 GMP suites (Grade C/B), c. 20 sqm each
  • Co-located at a major clinical centre with ATMP trial experience
  • Flexible access to facilities, streamline costs to production campaigns only

Quality & Regulatory Compliance

  • Qualified Person consultancy services
  • ATMP regulatory advice and guidance
  • Audit provision across the ATMP supply chain
  • Design and validation of aseptic manufacuring facilities

Our Combined Experience

130 years in Cell & Gene Therapy

Gained with over 20 different Cell & Gene Therapy companies and academic centres and in collaboration with over 50 institutions

250 years in life sciences

Greater than 90% of all staff have life science graduate degrees

More than 70% have post-graduate qualifications

160 scientific paper and article publications

Staff have prepared more than 1,300 Doses of cell and gene products administered to patients

Autologous >600 patients
Allogenic >700 patients

Been involved with over 25 different cell & gene products produced for ‘first in human’ studies

Extensive experience with licensing, accreditation and governance from UK & EU regulatory and professional bodies

Meet the Team

Colin Sims

Chief Executive Officer

Stuart Curbishley

Chief Development Officer & Chief Manufacturing Officer

John Campbell

Chief Scientific Officer

Kwok Pang

Chief Digital Officer

Ken MacRitchie

Chief Commercial Officer

Neil McGowan

Eligible QP

Cristina Sum

Quality Director

Simon Lau

Head of Operations

Matthew Symes

Head of Strategy & Finance

Toby Proctor

Head of MSAT

Katarzyna Starowicz

PD Scientist

Rayyanah Usmani

PD / GMP Scientist

Ridhi Gada

GMP Scientist

Shaun Day

GMP Scientist

Konstantina Petkou

PD Scientist

Claire Parmar-Fleming

Office Manager

Meet the Board of Directors

Muzammil Mansuri


Hilary Malone


Carol Lynch

Board Observer

Colin Sims

Director & CEO

Jonathan Hay


Igor Linshits



As a venture-backed business we always welcome discussions with new investors. For investors, please contact Colin (our CEO) to talk more.


We are a growing speciality enterprise and are always looking for the very best talent to join our team. Please click below or email us at info@adthera.bio to submit your CV and discuss more.

Contact us

Get in touch with the adthera team


We look forward to hearing from you.

Reach us at the email or address below, or alternatively use the contact form and we’ll get back to you as soon as possible.

+44 121 827 1000

Birmingham | Lyndon House, 62 Hagley Rd, Birmingham B16 8PE
London | 15 Stukeley Street, London WC2B 5LT